Astria TherapeuticsATXS
ATXS
About: Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Employees: 78
0
Funds holding %
of 7,430 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
43% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 30
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
1% less capital invested
Capital invested by funds: $311M [Q1] → $310M (-$1.91M) [Q2]
1.49% less ownership
Funds ownership: 103.35% [Q1] → 101.87% (-1.49%) [Q2]
10% less funds holding
Funds holding: 115 [Q1] → 104 (-11) [Q2]
39% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 23
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$16
144%
upside
Avg. target
$21
221%
upside
High target
$26
297%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Jonathan Wolleben | 297%upside $26 | Market Outperform Maintained | 13 Aug 2025 |
HC Wainwright & Co. Joseph Pantginis | 144%upside $16 | Buy Reiterated | 13 Aug 2025 |
Financial journalist opinion
Based on 4 articles about ATXS published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Does Astria Therapeutics (ATXS) Have the Potential to Rally 333.88% as Wall Street Analysts Expect?
The mean of analysts' price targets for Astria Therapeutics (ATXS) points to a 333.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
Business Wire
1 week ago
Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. “Delivering on navenibart's best-in-class potential is our top priority, and enrollment in the global Phase 3 ALPHA-ORBIT trial is well underway with active sites across the U.S., U.K., Canada, Hong Kong, and S.
Neutral
Business Wire
2 weeks ago
Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it has exclusively licensed development and commercialization rights in Japan to Kaken Pharmaceutical, Co., Ltd., a Japanese specialty pharmaceutical company, for navenibart, a long-acting investigational monoclonal antibody inhibitor of plasma kallikrein, in Phase 3 development for the preventativ.
Neutral
Business Wire
3 weeks ago
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 180,000 shares of Astria's common stock on August 1, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were gran.
Neutral
Business Wire
1 month ago
Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit
BOSTON, Mass.--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four posters at the 2025 US Hereditary Angioedema Association (HAEA) National Summit, taking place July 10-13, 2025 in Baltimore, Maryland. Timothy Craig, D.O., Professor of Medicine, Pediatrics, and Biomedical Sciences at Penn State University in Hershey, Pennsylvania, will.
Neutral
Business Wire
1 month ago
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 119,860 shares of Astria's common stock on July 1, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were grante.
Neutral
Business Wire
2 months ago
Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will participate in a panel discussion at the Oppenheimer Innovators in Immunology & Inflammation (I&I) Summit on June 25 in New York, NY. Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a panel titled, “Advances in Dermatology: AD and CSU” on Wednesday, June 25 at 10:.
Neutral
Business Wire
2 months ago
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the target enrollment group in the ongoing ALPHA-SOLAR long-term open-label trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. These results demonstrated robust overall reduction in the mon.
Neutral
Business Wire
2 months ago
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four posters at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, taking place June 13-16, 2025 in Glasgow, United Kingdom. Dr. William Yang, M.D., FRCPC, FAAAAI, Managing Director and Chair, Ottawa Allergy Research Corporation, will present combined i.
Neutral
Business Wire
2 months ago
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 62,000 shares of Astria's common stock on June 2, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted.
Charts implemented using Lightweight Charts™